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The SuperLinezolid mediumwas developed for screening resistance to linezolid (LZD) in Gram-positive bacteria
(Staphylococcus spp., Enterococcus spp.). It was evaluated using LZD-susceptible (n=20) and LZD-resistant (n=
17) Gram-positive isolates. The sensitivity was found to be 82% at 24 h (3 out of 17 isolates being missed), and
reached 100% at 48 h. At 48 h, a single LZD-susceptible isolate grew (speciﬁcity 95%). By testing stools spiked
with LZD-resistant Gram-positive strains, an excellent performance of the medium was observed, with a lowest
detection limit ranging from 101 to 102 CFU/ml. Overall, this medium is accurate for detection of LZD-resistant
Gram-positive isolates after 24 h of culture.
Oxazolidinone antibiotics such as linezolid (LZD) are increasingly
used as a consequence of an increased rate of multidrug-resistant
Gram-positive pathogens (Leach et al., 2011). Considering thewide dif-
fusion of methicillin-resistant Staphylococcus aureus and Staphylococcus
epidermidis isolates worldwide (Purrello et al., 2016), as well as the
wide diffusion of vancomycin-resistant Enterococcus faecium and
Enterococcus faecalis (Zahedi Bialvaei et al., 2017), there is a signiﬁcant
need to rely on the use of LZD to treat infections caused by those
multidrug-resistant isolates (Cattoir and Giard, 2014). Therefore, it not
surprising that occurrence of LZD-resistant isolates is now increasingly
reported, including in S. aureus, S. epidermidis, E. faecium, and
E. faecalis (Bi et al., 2017; Bourgeois-Nicolaos et al., 2014; Gu et al.,
2013). Consequently, accurate and rapid identiﬁcation of LZD-resistant
isolates is needed.
The main mechanism of resistance to LZD in Gram-positive bacteria
corresponds to a speciﬁc mutation (G2576 T) in the 23S rRNA gene,
preventing the binding of the drug to its target, i.e. the ribosome
(Sadowy et al., 2018). Some other mutations have been reported in
the 23S rRNA gene, leading to modiﬁcations of the L3, L4, and L22 ribo-
somal proteins, but they aremuch less frequent (Bi et al., 2017; Gu et al.,
2013; Pfaller et al., 2017a, 2017b).
In addition, acquired transferable LZD resistance genes have been re-
ported, namely the cfr, cfr(B), cfr(C), optrA, and poxtA genes (Sadowy,
2018). The cfr gene encodes a methylase modifying the C-8 position of
A2503 residue in the 23S rRNA methylases (Kehrenberg et al., 2005;
Schwarz et al., 2000), and confers resistance not only to LZD but also
to phenicols, lincosamides, pleuromutilins, and streptogramins (so
called PhLOPSA resistance phenotype), but noticeably spares the novel
oxazolidinone tedizolid (Long et al., 2006). This genehas been identiﬁed
in S. aureus, enterococci, Streptococcus suis, and Bacillus spp., but also in
several Gram-negative bacteria such as Escherichia coli and Proteus
vulgaris. The cfr(B) gene sharing 72% nucleotide identity with cfr was
found in S. aureus, also conferring a PhLOPSA resistance phenotype
(Marín et al., 2015). The cfr(C) gene encoding a protein sharing ca.
55% amino acid identity with Cfr(A) and Cfr(B) was found in
Campylobacter spp. (Tang et al., 2017).
In addition to those Cfr-like 23S rRNA methylases, another acquired
resistance trait to LZD has been reported, being OptrA (Wang et al.,
2015). It belongs to the ABC-F family of ATP-binding proteins, and has
been characterized as a ribosomal protection protein. The correspond-
ing gene was ﬁrst identiﬁed in E. faecalis, and later in Staphylococcus
sciuri and Streptococcus gallotycus (Sharkey et al., 2016).
Finally, another ribosomal protection protein, PoxtA, was recently
identiﬁed from a human methicillin-resistant S. aureus (MRSA) clinical
isolate isolate, and further identiﬁed in E. faecalis and E. faecium of
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which should be cited to refer to this work.
animal origin (Antonelli et al., 2018). That resistance mechanism con-
fers reduced susceptibility not only to oxazolidinone, but also to tetracy-
clines and phenicols.
Taking in account the potential clinical threat represented by a diffu-
sion of LZD-resistant strains, our aim was to develop a selective culture
medium for screening of LZD-resistant bacteria both among human and
animal isolates.
1. Material and methods
1.1. Preparation of the SuperLinezolid medium
The necessity to prevent contamination byGramnegatives and fungi
was taken in account for the development of this medium. Based on our
own experience of developing screeningmedia (Nordmann et al., 2012,
2016), the optimal medium retainedwas based on the Brain Heart Infu-
sion (BHI) medium (ref 3,564,014; Bio-Rad, Cressier, Switzerland). This
medium was rich enough to enhance the growth of the Gram-positive
isolates we tested.
To determine the optimal concentrations of each compound of the
SuperLinezolid medium, a series of different preliminary tests was
performed, using six linezolid-resistant and two linezolid-susceptible
isolates, including Staphylococci and Enterococci strains. Using an inocu-
lum with an optical density of 0.5 Mac Farland (inoculum of ~108 CFU/
ml), a 1000-fold dilution of the strains to be tested wasmade in normal
saline solution and a 100-μl volumewas plated onto the SuperLinezolid
medium. To quantify the viable bacteria in each dilution, BHI agar me-
diumwas inoculated concomitantlywith 100 μl of suspension and incu-
bated overnight at 37°C. A range of concentrations varying from 0.25,
0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4mg/L was tested, and the 1.5 mg/L concen-
tration was retained since it allowed to obtain the optimal sensitivity
and speciﬁcity values. Colistin sulfate (tablets, MAST DIAGNOSTICS,
Merseyside, UK) was added in the medium at a ﬁnal concentration of
15 μg/ml to prevent the growth of colistin- susceptible Gram-negative
isolates. In addition, considering that growth of colistin-resistant
Gram-negative strains might be a source of contamination (particularly
with species being intrinsically resistant or heteroresistant to colistin
such as Proteus spp., Serratia spp., Hafnia spp., or Enterobacter cloacae)
(Poirel et al., 2017), aztreonam was added at a concentration of 2 μg/ml.
While addition of aztreonam contributed to inhibit growth of Gram-
negative bacteria (unless they produced broad-spectrum ß-lactamases),
it did not modify the growth of the Gram-positive bacteria tested,
including LZD-susceptible and -resistant isolates. Amphotericin B
(Bristol-Myers-Squibb, Rueil-Malmaison, France) was added as an anti-
fungi molecule at a ﬁnal concentration of 5 μg/ml. Cultures were
incubated at 37°C during 18 h. When no growth was observed after
24 h, the incubation period was extended to 48 h to deﬁnitely assess
that no growth actually occurred.
The instructions for the preparation of SuperLinezolid medium are
indicated in Table 1. The stock solutionsmay be kept at−20°C. For pre-
paring the SuperLinezolid medium, the diluted powder of BHI was
autoclaved at 121°C for 15 min. After cooling this medium for one
hour at 56°C, the antibiotic stock solutions were added (Table 1). Once
poured, the plateswere stored at 4°C and protected fromdirect light ex-
posure. The SuperLinezolid plates were kept one month and no major
effect on its performances was noticed over time (data not shown).
(See Fig. 1.)
A total of thirty-seven isolates of various Gram-positive species
(Enteroccocus faecium, Enterococcus faecalis, Enterococcus casseliﬂavus,
Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus
capitis) recovered in France were tested to evaluate the performance
of the SuperLinezolid medium. Seventeen of those isolates were resis-
tant to LZD, and twenty isolates were susceptible. In addition, a total
of eleven Gram-negative isolateswere tested, including Enterobacteria-
ceae (n = 9), Pseudomonas aeruginosa (n = 1), and Acinetobacter
baumannii (n = 1) isolates. All those isolates were clonally-unrelated
(data not shown).
The lowest limit of detectionwith the SuperLinezolidmediumwasde-
termined for all the tested strains. Using an inoculumwith an optical den-
sity of 0.5 McFarland standard (inoculum of ∼108 CFU/ml), serial 10-fold
dilutions of the isolates were made in normal saline, and 100-μl portions
were plated onto the SuperLinezolid medium. To quantify the viable
Table 1
Preparation of the SuperLinezolid medium.
Compounds Stock solution Quantity or volume to adda Final concentration
BHI agar powder - 14.8 g 3.7%
Distilled water - 400 ml
Linezolid 2 mg/ml 300 μl 1.5 μg/ml
Aztreonam 10 mg/ml 80 μl 2 μg/ml
Colistin sulfate 15 mg/ml in water in glass tubes 400 μl 15 μg/ml
Amphotericin B 20 mg/ml in D(+)-glucose 10% 100 μl 5 μg/ml
a The volume of 400 ml of SuperLinezolid medium was for twenty plates.
Fig. 1. LZD-resistant S. epidermidis (A), and E. faecium (B) growing onto the SuperLinezolid medium.
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bacteria in each dilution, BHI agar was inoculated concomitantly with
100 μl of suspension and was incubated overnight at 37°C. The number
of viable colonieswas counted after 24 h of culture at 37°C. The sensitivity
and speciﬁcity cut-off values were set at 1 × 103 CFU/ml i.e., a limit value
of 1×103 CFU/ml and abovewas considered as « not efﬁciently detected »
(Schwarz et al., 2000).
Spiked stools were also tested using this selective culture medium,
done in triplicate. Spiked fecal samples were made by adding 100 μl of
each strain dilution to 900 μl of fecal suspension that was obtained by
suspending 5 g of freshly pooled feces from three healthy volunteers
in 50 ml of distilled water, as done previously (Nordmann et al.,
2016). A non-spiked fecal suspension was used as negative control.
The lowest detection limit was determined by plating 100 μl of each
dilution on the screening medium. The sensitivity and speciﬁcity were
determined using the same cut-off value set at ≥103 CFU/mL
(Nordmann et al., 2016).
MICs of LZDwere determined using the brothmicrodilutionmethod
in Mueller-Hinton broth, as recommended by the CLSI (Clinical and
Laboratory Standards Institute, 2018). For each strain, an inoculum cor-
responding to 5 × 105 CFU/ml was distributed in the 96-well tray
(Sarstedt, Nümbrecht, Germany). The evaluation of the selective me-
dium was performed in triplicate.
According to the CLSI and EUCAST breakpoints (www.eucast.org/
clinical_breakpoints/), Staphylococcus spp. and Enterococcus spp. iso-
lates with MIC values of LZD ≤ 4 mg/L are categorized as susceptible,
whereas those with MIC values ≥8 mg/L are categorized as resistant.
2. Results
Overall, all LZD-resistant Gram-positive isolates tested grew on the
SuperLinezolid medium after 24 h, except three LZD-resistant
S. epidermidis isolates (HM-1, HM-2, and HM-6) that did not grow
after 24 h of incubation (even at a concentration of 103 CFU/ml), but
grew after 48 h (Table 2). As expected, no growth was observed for
the 11 Gram-negative isolates tested.
The sensitivitywas found to be 82% at 24 h (3 out of 17 isolates being
missed), and reached 100% at 48 h. At 48 h, a single LZD-susceptible iso-
late grew (speciﬁcity 95%).
For all the LZD-susceptible isolates, the lowest limit of detectionwas
found above the cut-off value of 103 CFU/ml, being in fact ≥1 × 106 CFU/
ml (Table 2). By contrast, all the LZD-resistant isolates grew on the
SuperLinezolid medium in 24 h and the lowest limit of detection was
below the cut-off value. All LZD-susceptible Gram-positive did not
growth after 24 h of incubation when the inoculum was up to
103 CFU/ml; small colonies were obtained only for a single isolate
(S. aureus 2973) after 48 h of incubation when using this same inocu-
lum. Therefore, a speciﬁcity of 100% was observed after a 24-h culture.
Finally, no Gram-negative isolate grew after either 24 h or 48 h of
incubation.
The spiked stools containing LZD-resistant strains grew with a low-
est detection limit ranging from 101 to 102 CFU/ml (Table 3), thus nicely
corresponding to the required sensitivity. In addition, no false-positive
isolate was recovered, thus showing an excellent speciﬁcity.
3. Discussion
We developed here a selective medium allowing screening and de-
tection of Gram-positive bacteria exhibiting resistance to LZD. Consider-
ing that LZD-resistant isolates are currently emerging in different parts
of theworld, this selectivemediummay be used to perform prospective
screening, and epidemiological surveys. Some surveys had used media
supplemented with LZD for selection of LZD-resistant isolates but nei-
ther systematic evaluation nor development of such media had been
performed (Bourgeois-Nicolaos et al., 2014; Lode et al., 2001).
The SuperLinezolid medium may detect all clinically-relevant bacte-
rial species exhibiting resistance to LZD, regardless of the resistance
Table 2
Lowest limits of detection of the SuperLinezolid medium for linezolid-resistant isolates.
Strains MIC of linezolid (mg/L) Growth on the
SuperLinezolid
medium
At 24 h
At 48 h
E. faecium CNR-15-307 32 + +
S. aureus 2015S421 8 + +
S. aureus ST2015–1386 32 + +
S. capitis ST 2015–2014 N256 + +
S. epidermidis ST2014–0603 8 + +
S. epidermidis A N256 + +
S. epidermidis 2 N256 + +
S. epidermidis 22 N256 + +
S. epidermidis ST
2015–1734
N256 + +
S. epidermidis ST
2015–1739
N256 + +
S. epidermidis LESC 256 + +
S. epidermidis HM-1 16 − +
S. epidermidis HM-2 16 − +
S. epidermidis HM-3 256 + +
S. epidermidis HM-4 32 + +
S. epidermidis HM-5 256 + +
S. epidermidis HM-6 8 − +
E. faecalis ATCC 29212 2 − −
E. faecalis N95 1 − −
E. faecalis N89 1 − −
E. faecalis 2953 2 − −
E. faecalis 2094 2 − −
E. faecalis 2146 2 − −
E. faecalis 2147 2 − −
E. casseliﬂavus 2149 2 − −
S. aureus ATCC 29213 2 − −
S. aureus C1013 1 − −
S. aureus C1014 1 − −
S. aureus 2954 2 − −
S. aureus 2092 2 − −
S. aureus 2973 2 − +
S. aureus 3108 2 − −
S. aureus 2959 2 − −
S. aureus 2732 1 − −
S. epidermidis N30 1 − −
S. epidermidis N79 1 − −
S. epidermidis 2145 2 − −
Table 3
Lowest limits of detection of the SuperLinezolid medium for a series of linezolid-resistant isolates in spiked stools.⁎
Strains Species Genotype MIC of linezolid (μg/ml) Lowest limit of detection
2015S421 S. aureus Cfr+ 8 101
CNR E. faecium CfrC + OptrA+ 32 101
ST2015–2014 S. capitis Mutations RNA T/2319/C; G/2576/T N256 102
ST2014–0603 S. epidermidis Mutations RNA T/2504/A; C/2534/T 8 101
LESC S. epidermidis ND (cfr-; optrA-) 256 101
HM-2 S. epidermidis ND (cfr-; optrA-) 16 101⁎
HM-3 S. epidermidis Cfr+ 256 101
HM-6 S. epidermidis Cfr+ 8 102
⁎ Only after 48 h growth.
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mechanism, and regardless of their resistance level to LZD. Growth of
most isolates showing MICs of LZD ranging from 8 to N256 μg/ml on
this selectivemediumwas conﬁrmed. These resistant isolateswere either
S. aureus, S. epidermidis, E. faecium, or S. capitis. Failure to detect any LZD-
resistant isolate tested was observed in three cases after a 24-h culture,
corresponding to S. epidermidis isolates having an MIC at 8 or 16 μg/ml,
therefore close to the breakpoint. The sensitivity was improved and all
isolates detected at 48 h; however, the speciﬁcity at 48 h was lower,
with 6 out of 20 LZD-susceptible isolates being recovered. It seems there-
fore that a 24-h growth is recommended. An extended evaluation of this
selective medium is needed to guarantee high speciﬁcity and high sensi-
tivity of the selection.Wemay admit that our study was performed with
a limited number of isolates (due to limited isolates available in our col-
lection), nevertheless we believe that the performances of the
SuperLinezolid medium as obtained here do have a signiﬁcant value.
Thismedium offers the possibility either to assess the LZD resistance
feature by selecting such isolates after re-striking of mixed cultures, but
most of all to select for those LZD-resistant isolates from stools in a con-
text of direct screening.
Therefore, the use of this selective medium may contribute to rap-
idly identify carriers of LZD-resistant isolates, and consequently to rap-
idly implement infection control measures in order to limit their spread
in hospital settings.
Finally, this mediummay be also useful for screening food-producing
animal reservoirs. Indeed, resistance to LZD in Enterococci has been in-
creasingly identiﬁed particularly in swine, poultry and cattle, mainly in
China (Fang et al., 2018). An animal reservoir of LZD-resistant strains
has been demonstrated for a series of bacterial species, including
E. faecalis and E. faecium (pigs and chicken), but also for Enterococcus
gallinarum, Enterococcus casseliﬂavus, Enterococcus thailandicus, and En-
terococcus suis (pigs) (Sadowy, 2018). Prospective surveys may therefore
be conducted by veterinary networks in order to evaluate the rate of LZD-
resistant Gram positives in animal husbandries, and identify possible
reservoirs.
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